BioMedSA’s Board of Directors approved 2 new members in March 2026: Eich, Inc. and Integral LifeScience Advisors.
Integral LifeScience Advisors is a consulting firm that supports life‑science and healthcare companies across multiple stages of development. The firm provides medical and clinical expertise, including clinical development planning, evidence generation strategy, and support for interactions with healthcare stakeholders. It also offers broad commercial and corporate services such as market assessment, commercialization strategy, organizational planning, and executive advisory support. Together, these services are intended to help companies align scientific development with business objectives and prepare for clinical, regulatory, and market milestones.
Eich, Inc. operates in the healthcare technology and life‑sciences space, with a focus on oncology and advanced care delivery. The company develops patient‑facing mobile applications, prototypes, and commercial healthcare products intended for real‑world clinical use. Its work also includes novel medicine development and the application of artificial intelligence to aggregate clinical data. Across these efforts, EICH aims to improve patient engagement, support clinical trial participation, and advance evidence‑driven healthcare solutions.